Asset Details
Do you wish to reserve the book?
Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma
Do you wish to request the book?
Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical experience with immunotherapy in patients with diffuse intrinsic pontine glioma
2025
Overview
The objective of the article is to report the case of three patients with diffuse intrinsic pontine glioma (DIPG) treated with immunotherapy. In particular we report the data related to the treatments’ efficacy and tolerance.To achieve this, we review the medical records in the Paediatric Oncology and Haematology Unit of HM Hospitales/Centro Integral Oncológico Clara Campal (CIOCC). We focused on patients diagnosed with DIPG who were administered oncolytic viruses followed by immune checkpoint inhibitors (ICI) (pembrolizumab, anti PD-1) plus a concomitant antiangiogenic agent (bevacizumab).The results we obtained showed the three paediatric DIPG patients studied presented good tolerance, with disease stabilisation for approximately 5 months after immunotherapy. However, subsequent clinical worsening required clinicians to change the patients’ treatment.In conclusion, immunotherapy combined with other conventional antineoplastic treatments (chemotherapy, radiotherapy) is postulated as a very promising future therapeutic option. However, further research is warranted in the paediatric population to demonstrate safety and effectiveness.
Publisher
British Medical Journal Publishing Group,BMJ Publishing Group LTD
Subject
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ Bevacizumab - administration & dosage
/ Brain Stem Neoplasms - drug therapy
/ Brain Stem Neoplasms - immunology
/ Brain Stem Neoplasms - therapy
/ Child
/ Diffuse Intrinsic Pontine Glioma - drug therapy
/ Diffuse Intrinsic Pontine Glioma - immunology
/ Diffuse Intrinsic Pontine Glioma - therapy
/ Female
/ Glioma
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - administration & dosage
/ Immune Checkpoint Inhibitors - therapeutic use
/ Male
/ Oncolytic Virotherapy - methods
/ Patients
/ Toxicity
/ Tumors
